The State of Microbiocenosis of the Large Intestine in Children against the Background of Systemic Therapy with an Antimycotic
The study was aimed at evaluating the effect of a tablet antimycotic on the normal flora of the large intestine in the treatment of scalp microsporium in children. Materials and methods. The microbiota of the large intestine was studied using bacteriological analysis in 48 patients from rural areas, aged 3 three to 12 years, with microsporium of the scalp. The studies were conducted before the use of griseofulvin at a dose of 21–22 mg/kg per day for six weeks, on the tenth and twentieth days of therapy. It was found that by the 31.01 ± 2.85 day of treatment, a full clinical effect was observed, including the absence of fluorescence in the UFL and the eradication of the pathogen in the foci. Before treatment, the normal flora of the large intestine of rural children was dominated by a bifidus-dominant composition. By the twentieth day of treatment, the average concentrations of bifidobacteria had decreased to 106 CFU/g (a decrease of 40.0 %) (p ⩽ 0.05) and lactobacilli had decreased to 105 CFU/g (a decrease of 28.6 %) (p ⩽ 0.05), compared to the initial level. Conclusion. The study revealed a side effect of griseofulvin during long-term oral administration, which is expressed in a decrease in the concentration of the main families of normal flora in the microbial landscape of the large intestine of children without combining it with drugs that normalize the species composition of the intestinal microflora.
Khmelnitsky R.А., Khmelnitskaya Yu.I., Vislobokov А.V. 2026. The State of Microbiocenosis of the Large Intestine in Children against the Background of Systemic Therapy with an Antimycotic. Challenges in Modern Medicine, 49(1): 26–38 (in Russian). DOI: 10.52575/2687-0940-2026-49-1-26-38. EDN: IUKSHG
While nobody left any comments to this publication.
You can be first.
Andreev V.A., Stetsyuk O.U., Andreeva I.V. 2022. Probiotics: An Unresolved Problem. Clinical Microbiology and Chemotherapy. 24(4): 345–360 (in Russian). doi: 10.36488/cmac2022.4.345-360
Klimko N.N. 2017. Mycoses: Diagnosis and Treatment. A Guide for Doctors. 3rd edition. Moscow: Pharmtek, 272 p. (in Russian).
Kostyuchenko L.A., Kharitonova N.S., Vdovin V.M. 2018. The Effectiveness of Using a Vitamin Complex: Vitamin D and Vitamin K (Literature Review). Bulletin of Medical Science. 11(3): 33–40 (in Russian).
Kokorev D.A., Strazhina E.A., Kabanova N.P., Yankovaya Z.A., Konstantinov D.Y., Lyamin A.V. 2025. Features of Pathogenicity Factors of Enterobacteriaceae Family Members Involved in the Development of Necrotizing Enterocolitis. Medical Council. (19): 154–165 (in Russian). https://doi.org/10.21518/ms2025-348
Kubanov A.A., Bogdanova E.V. 2021. The Result of the Activities of Medical Organizations Providing Medical Care in the Field of Dermatovenerology in 2020: Work in a Pandemic: Bulletin of Dermatology and Venereology. 97(4): 8–33 (in Russian). https://doi.org/10.25208/vdv1261
Lagutin M.B. 2025. Visual Mathematical Statistics. Binom: Knowledge Laboratory. 472 p. (in Russian).
Livzman M.A., Borodin D.S., Abdulkhanov S.R. 2025. Constipation, Intestinal Microbiota and Comorbid Pathology: The Search for an Optimal Approach to Patient Management. Breast Cancer. MRJ. Medical review. 9(9): 596–605 (in Russian). doi: 10.32364/2587-6821-2025-9-9-9
Martynov N.S., Ponezheva Zh.B., Kulikova N.G., Bityunina L.A., Lazareva E.N., Usenko D.V., Vdovina E. 2025. Systemic Inflammation and Intestinal Microbiocenosis in COVID-19: The Role of Macrophage Inflammatory Proteins in the Pathogenesis of the Disease. MRJ. Medical review. 9(5): 259–265 (in Russian). doi: 10.32364/2587-2025-9-5-1
Medvedeva T.V., Leina L.M., Chilina G.A., Petunova Ya.G., Pchelin I.M. 2020. Microsporia: Current Views on the Problem (Description of Clinical Cases and Literature Review). Problems of Medical Mycology. (2): 12–21 (in Russian). doi: 10.24412/1999-6780-20202-12-21
Meskina E.R. 2025. Treatment of Acute Infectious Diarrhea in Children: Current Trends and Open Issues. RMJ. Mother and Child. 8(3): 263–270 (in Russian). doi: 10.32364/2618-8430-2025-8-3-12
Russian Ministry of Health. 2003. "Protocol for the Management of Patients. Intestinal Dysbiosis" / OST 91500.11.0004-2003. Order of the Ministry of Health of the Russian Federation No. 231. 06/09/2003. (in Russian) (Electronic Resource) URL: https://www.base,garant.ru (access date 07.10. 2025)
Pakhomovskaya N.L., Venedittova M.M. 2018. Healthy Colonization in Children – Strong Immunity. Meditsinskiy sovet. 17: 199–205 (in Russian). https://doi.org/10.21518/2079-701X-2018-17-199-205
Ruzhentsova T.A., Garbuzov A.A., Bayrakova A.L. 2025. The Effect of Probiotic Therapy on the Clinical Manifestations of Neuropsychiatric Disorders in Patients with Dysbiotic Changes. RMJ. Medical Review. (5): 2 2–28 (in Russian). doi: 10.32364/2225-2282-2025-5-5
Safina D.D., Abdulkhakov S.R., Amirov N.B. 2021. Intestinal Microbiota and its Significance for Human Health. Bulletin of Modern Clinical Medicine. 14(5): 81–94 (in Russian). doi: 10.20969/VSKM.2021.14(5).81-94
Stepanov M.S., Karpunina N.S., Spasenkov G.N. 2025 The Microbial Composition of the Colon and the Levels of Certain Pro-Inflammatory Serum Molecules in the Long-Term Period in Patients with Myocardial Infarction. RMJ; Medical Review. 9(5): 275–280 (in Russian). doi: 10. 32364/2587-6821-2025-9-5-3
Fomochkina Е.А. 2023. Microsporia (Ringworm) (in Russian). (Electronic Resource) URL: https://probolezny.ru/mikrosporiya / (access date 04.15.2025)
Federal Clinical Guidelines. Dermatovenerology. 2016. Skin Diseases. Sexually Transmitted Infections (2016). Kubanova A.A. (Edit.). Moscow: Delovoy Express, 768 p. (in Russian).
Shenderov B.A., Golubev V.L., Danilov A.V., Prishchepa A.V. 2016. Human Intestinal Microbiota and Neurodegenerative Diseases. Poliklinika. 1–1: 7−13 (in Russian).
Yakovlev A.B. 2019. Systemic Therapy of Mycoses of Hairy Skin Areas: The Possibilities of Adjuvant Drugs. Effective Pharmacotherapy. 15(11): 6–10 (in Russian). doi: 10.33978/2307-3586-2019-15-11-6-10
Abdulgadir A., Engers J., Al-Sadi. 2023. Role of Bifidobacterium in Modulating the Intestinal Epithelial Tight Junction Barrier: Current Knowledge and Perspectives. Curr Dev Nutrition. Oct 30; 7(12); 102026. doi: 10.1016/j.cdnut.2023.102026
Al Bander Z., Nitert M.D., Mousa A., Naderpoor N. 2020. The Gut Microbiota and Inflammation: An Overview. International Journal Environmental Research. 17(20): 7618. doi: 10.3390/ijerph17207618
Bajaj P., Sharma M. 2025. Chrononutrition and Gut Health: Exploring the Relationship Between Meal Timing and the Gut Microbiome. Curr Nutrition Rep. 2025 Jun 9; 14(1): 79. doi: 10.1007/s13668-025-00670-z
Enna S.J., Bylund D.B. xPharm: The Comprehensive Pharmacology Reference. 2008. (Electronicresource) URL:https://www.sciencedirect.com/referencework/9780080552323/xpharm-the-comprehensive-pharmacology-reference (access date 07.15. 2025)
Gusliakova O., Verkhovskii R., Abalymov A., Lengert E., Kozlova A., Atkin V., Nechaeva O., Morrison A., Tuchin V., Svenskaya Y. 2021. Transdermal Platform for the Delivery of the Antifungal Drug Naftifine Hydrochloride Based on Porous Vaterite Particles. Materials Science and Engineering: 119 p: 111428. doi: 10.1016/j.msec.2020.111428
Harmsen H.J.M., Wldeboer–Veloo А.С.М., Raangs G.C., Wagendorp А.А., Klijn N., Bindels J.G., Welling G.W. 2000. Analysis of Intestinal Flora Development in Breast–Fed and Formula–Fed Infants by using Molecular Identification and Detection Methods. Journal of Pediatric Gastroenterology and Nutrition. 30: 61–70. doi: 10.1097/00005176-200001000-00019
He Bao-Lin., Xiong Y., Hu Ten-Gen., Zong Min-Hua., Wu H. 2023. Bifidobacterium spp. as Functional Foods: A Review of Current Status, Challenges, and Strategies. Clinical Reviews in Food Scinsce and Nutrition. 63. (26): 8048–8065. doi: 10.1080/10408398.2022.2054934
Higuchi T., Furuichi M., Maeda N. Tsugawa T., Ito K. 2024. Effects of Probiotics in Children with Acute Gastroenteritis: A Systematic Review and Meta-Analysis Focusing on Probiotics Utilized in Japan. Journal Infection Chemother. 30(4): 337–342. doi: 10.1016/j.jiac.2023.11.005
LeBegue C.E., Love B.L., Watt M.D. 2020. Microbes as Drugs: The Potential of Pharmabiotics. Pharmacotherapy. 44(2): 102–106. doi: 10.1002/phar. 2357
Marole T., Sinbanda T., Buys E. 2024. Assessing Probiotic Viability in Mixed Species Yogurt Using a Novel Propidium Monoazide (PMAxx)-Quantitative PCR Method. Front Microbiology. Feb. 8(15): 1325268. doi: 10.3389/fmicb.2024/1325268.eCollection2024
Marto J., Vitor C., Guerreiro A., Severina C., Eleut´erio C., Ascenso A., Simo˜es S. 2016. Ethosomes for Enhanced Skin Delivery of Griseofulvin. Colloids end Surfaces B: Biointerfaces. 146: 616−623. https://doi.org/10.1016/j.colsurfb.2016.07.021
Mpountouridis A., Tsigalou C., Bezirtzoglou I., Bezirtzoglou E., Stavropoulou E. 2024. Gut Microbiome in Non-Alcoholic Fatty Liver Disease. Front Gastroenterol. (3): 1534431. doi: 10.3389/fgstr.2024.1534431
Nassir M., Ramli M., Ghazali M., Jaffer M., Hamid H., Mehat M., Hein Z. 2024. The Microbiota-Gut-Brain Axis: Key Mechanisms Driving Glymphopathy and Cerebral Small Vessel Disease. Life (Basel). Dec 24; 15(1): 3. doi: 10.3390/life15010003
Olteanu G., Ciucă-Pană M-A., Busnatu Ș., Luplisa D., Neacsu S., Mititelu M., Musus A., Lonita-Mindracan C-B., Boroghina S. 2024. Unraveling the Microbiome-Human Body Axis: A Comprehensive Examination of Therapeutic Strategies, Interactions and Implications. Int J Mol Sci. 25(10): 5561. doi: 10.3390/ijms25105561
Pant A., Maiti T., Mabajan D., Das B. 2023. Human gut Microbiota and Metabolism. Review. Microb Ecologi. 86(1): 97–111. doi: 10. 1007/s00248-022-02081-x
Poeta M., Del Bene M., Lo Vecchio A., Guarino A. 2024. Acute Infectious Diarrhea. Adv Exp Med Biol. 2024; 1449: 143–156. doi: 10.1007/978-3-031-58572-2_9
Sibanda T., Marole T., Thomashoff U., Thantsha M. 2024. Bifidobacterium Species Viability in Dairy-Based Probiotic Foods: Challenges and Innovative Approaches for Accurate Viability Determination and Monitoring of Probiotic Functionality. doi: 10.3389/fmicb.2024.1327010
Singh S., Patil V.M., Paliwal S.K., Masand N. 2024. Nanotechnology-based Drug Delivery of Topical Antifungal Agents. Pharmaceutical Nanotechnology. 12(3): 185–196. doi: 10.2174/2211738511666230818125031
Thursby E., Juge N. 2017. Introduction to the Human Gut Microbiota. Biochemical Journal. 474(11): 1823–1836. doi:10.1042/BCJ20160510
Tsubokawa M., Nishimura M., Mikami T., Ishida M., Hisada T., Tamada Y. 2022. Association of Gut Microbial Genera with Heart Rate Variability in the General Japanese Population: The Iwaki Cross-Sectional Research Study. Metabolites. 12(8): 730. doi: 10.3390/METABO12080730
Vignesh S.D., Vijayakumar T.M., Nandimandalam S.S. 2024. Impact of Food Intake and Slip Disturbances on Gut Microbiota. Reviw. Cureus. 16(10): e70846. doi: 10.7759/cureus.70846
Wei D., Yiru G., Li L., Sixiang S., Chen D. 2021. Striking Back against Fungal Infections: The Utilization of Nanosystems for Antufungal Strategies. International Journal Molecular Scientific. 22(18): 10104. doi: 3390/ijms221810104
Zhongvi M., Xiaoyou W., Chong L. 2020. Snrategies of Drug Delivery for Deep Fungal. Journal Farm Nanotechnologi. 8(5): 372–390. doi: 10.2174/2211738508666200910101923